Abstract Fri113: Targeting mitochondrial proteostasis in Barth syndrome-related cardiomyopathy

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Observational analysis reveals mitochondrial dysfunction in Barth syndrome, indicating CLPB as a potential therapeutic target.

CLPB loss improves mitochondrial function and calcium retention in Tafazzin-deficient cells, addressing Barth syndrome challenges.
Echocardiographic results demonstrate restored heart ejection fraction in CLPB knockdown mice, indicating therapeutic potential.
Transcriptional analysis shows elevated mitochondrial biogenesis markers in Tafazzin-deficient cells, supporting metabolic improvements.
Mitochondrial protein quality control plays a critical role in cardiac health, emphasizing CLPB's importance in Barth syndrome.

Kadam et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark